PRECISIONS

Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) is the first pulmonary fibrosis trial to use a genomic driven approach to identify patients most likely to respond to treatment. The trial is designed to validate earlier observations that patients with a particular variant in the TOLLIP gene responded better to treatment with N-Acetylcysteine (NAC). In addition, the study is using blood transcriptomics, proteomics, and genomics and the PFF registry cohort to identify a signature that distinguishes IPF from non-IPF interstitial lung diseases and identifies which genetic variants increase the risk of developing IPF.

PRECISIONS is a comprehensive, multicenter, multi-investigator study that is

advancing a precision-medicine approach to evaluating and managing patients with PF. Being able to distinguish IPF from non-IPF will provide a more accurate diagnosis.

Understanding the particular genotype and specific disease type will lead to more

effective and personalized treatments. We look forward to the day that disease

biomarkers and molecular classification of the disease from a simple blood test will be used to determine the right treatment for the right patient.

Fernando J. Martinez, MD, MS serves as the principal investigator on the project. Dr. Martinez is the Joseph D. Early Chair in Biomedical Research, Professor of Medicine, Vice Chair for Clinical and Translational Research, and Academic Chief of the Division of Pulmonary, Allergy, and Critical Care at UMass Chan Medical School. Imre Noth, MD serves as co-principal investigator of the study. Dr. Noth is Chief of the Division of Pulmonary and Critical Care Medicine at the University of Virginia.

Funding for this study was provided by a generous grant from the NIH and Three Lakes.

For more information, please see the following links and references:

www.pulmonaryfibrosis.org

PRECISIONS

If you are living with idiopathic pulmonary fibrosis, enroll now in the PRECISIONS study!

www.uvaphysicianresource.com

UVA Pulmonologist Unleashes Precision Medicine to Combat Pulmonary Fibrosis - Healthy Practice UVA Pulmonologist Unleashes Precision Medicine to Combat Pulmonary Fibrosis

Imre Noth, MD, helped secure $22 million in NIH and private funding to combat idiopathic pulmonary fibrosis (IPF) with precision medicine.

References:

“Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine” published in AM. J. Respir. Crit. Care Med. Reference

“Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis” published in AM. J. Respir. Crit. Care Med. Reference

“Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis interstitial Lung Disease” published in AM. J. Respir. Crit. Care Med. Reference

“Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial” published in BMC Pulm. Med. Reference